Key result
Review highlights no primary prevention benefit for aspirin alongside efficacy of novel lipid and antidiabetic agents.
Why the study?
Cardiovascular prevention remains a critical focus with ongoing uncertainties regarding lifestyle, novel treatments, and risk factors influencing cardiovascular risk and outcomes.
This annual review highlights key 2018 advancements in cardiovascular prevention, emphasizing the critical role of lifestyle modifications and emerging pharmacological therapies in reducing cardiovascular risk.
Supports aspirin avoidance in primary prevention; leaves open optimal sequencing of novel agents in broader populations.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Reiner et al. (2018) conducted a review in Cardiovascular disease prevention. The 2018 year in cardiology review highlights major advances in cardiovascular prevention, including the lack of benefit for aspirin in primary prevention and the efficacy of novel lipid-lowering and antidiabetic agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: